{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T22:27:55Z","timestamp":1772663275804,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s10840-021-01016-9","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T19:02:40Z","timestamp":1624302160000},"page":"379-388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diabetes mellitus aggravates ranolazine-induced ECG changes in rats"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7334-5603","authenticated-orcid":false,"given":"Habibeh","family":"Mashayekhi-Sardoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6000-3276","authenticated-orcid":false,"given":"Amir Hooshang","family":"Mohammadpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9697-2343","authenticated-orcid":false,"given":"Soghra","family":"Mehri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1880-0861","authenticated-orcid":false,"given":"Hossein","family":"Kamali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8656-1444","authenticated-orcid":false,"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2441-0421","authenticated-orcid":false,"given":"Mohsen","family":"Imenshahidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"issue":"2","key":"1016_CR1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrendo.2017.151","volume":"14","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88\u201398.","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"1016_CR2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jchf.2016.08.001","volume":"4","author":"FS Ahmad","year":"2016","unstructured":"Ahmad FS, et al. Hypertension, obesity, diabetes, and heart failure-free survival: the cardiovascular disease lifetime risk pooling project. JACC Heart Fail. 2016;4(12):911\u20139.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"1016_CR3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","volume":"124","author":"HC Kenny","year":"2019","unstructured":"Kenny HC, Abel ED. Heart failure in type 2 diabetes mellitus. Circ Res. 2019;124(1):121\u201341.","journal-title":"Circ Res"},{"issue":"23","key":"1016_CR4","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJM199812033392314","volume":"339","author":"Diabetes and Coronary Heart Disease","year":"1998","unstructured":"Diabetes and Coronary Heart Disease. N Engl J Med. 1998;339(23):1714\u20136.","journal-title":"N Engl J Med"},{"issue":"2","key":"1016_CR5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","volume":"3","author":"AD Shah","year":"2015","unstructured":"Shah AD, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1\u00b7 9 million people. Lancet Diabetes Endocrinol. 2015;3(2):105\u201313.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"1016_CR6","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","volume":"133","author":"CC Low Wang","year":"2016","unstructured":"Low Wang CC, et al. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation. 2016;133(24):2459\u2013502.","journal-title":"Circulation"},{"issue":"9994","key":"1016_CR7","first-page":"626","volume":"386","author":"L The","year":"2015","unstructured":"The L. Focusing on angina. The Lancet. 2015;386(9994):626.","journal-title":"The Lancet"},{"issue":"8","key":"1016_CR8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/BF03261926","volume":"51","author":"M Dostalek","year":"2012","unstructured":"Dostalek M, Akhlaghi F, Puzanovova M. Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin Pharmacokinet. 2012;51(8):481\u201399.","journal-title":"Clin Pharmacokinet"},{"issue":"233","key":"1016_CR9","first-page":"1","volume":"5","author":"M Vahabzadeh","year":"2015","unstructured":"Vahabzadeh M, Mohammadpour A-H. Effect of diabetes mellitus on the metabolism of drugs and toxins. J Clin Toxicol. 2015;5(233):1\u20138.","journal-title":"J Clin Toxicol"},{"issue":"11","key":"1016_CR10","doi-asserted-by":"crossref","first-page":"19339","DOI":"10.1002\/jcp.28644","volume":"234","author":"H Mashayekhi-Sardoo","year":"2019","unstructured":"Mashayekhi-Sardoo H, et al. The effect of diabetes mellitus on pharmacokinetics, pharmacodynamics and adverse drug reactions of anticancer drugs. J Cell Physiol. 2019;234(11):19339\u201351.","journal-title":"J Cell Physiol"},{"key":"1016_CR11","doi-asserted-by":"crossref","first-page":"6698743","DOI":"10.1155\/2021\/6698743","volume":"2021","author":"H Mashayekhi-Sardoo","year":"2021","unstructured":"Mashayekhi-Sardoo H, et al. Potential alteration of statin-related pharmacological features in diabetes mellitus. Biomed Res Int. 2021;2021:6698743.","journal-title":"Biomed Res Int"},{"issue":"5","key":"1016_CR12","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1476-5381.2011.01270.x","volume":"163","author":"M Dostalek","year":"2011","unstructured":"Dostalek M, et al. Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. Br J Pharmacol. 2011;163(5):937\u201347.","journal-title":"Br J Pharmacol"},{"issue":"10","key":"1016_CR13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3109\/00498257809069573","volume":"8","author":"LA Reinke","year":"1978","unstructured":"Reinke LA, Stohs SJ, Rosenberg H. Altered activity of hepatic mixed-function mono-oxygenase enzymes in streptozotocin-induced diabetic rats. Xenobiotica. 1978;8(10):611\u20139.","journal-title":"Xenobiotica"},{"issue":"2","key":"1016_CR14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0041-008X(88)90133-0","volume":"93","author":"JB Watkins 3rd","year":"1988","unstructured":"Watkins JB 3rd, Sanders RA, Beck LV. The effect of long-term streptozotocin-induced diabetes on the hepatotoxicity of bromobenzene and carbon tetrachloride and hepatic biotransformation in rats. Toxicol Appl Pharmacol. 1988;93(2):329\u201338.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"1016_CR15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0003-9861(88)90610-8","volume":"263","author":"ZG Dong","year":"1988","unstructured":"Dong ZG, et al. Mechanism of induction of cytochrome P-450ac (P-450j) in chemically induced and spontaneously diabetic rats. Arch Biochem Biophys. 1988;263(1):29\u201335.","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"1016_CR16","first-page":"119","volume":"37","author":"KE Thummel","year":"1990","unstructured":"Thummel KE, Schenkman JB. Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat. Mol Pharmacol. 1990;37(1):119\u201329.","journal-title":"Mol Pharmacol"},{"issue":"10","key":"1016_CR17","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S0006-2952(96)00526-6","volume":"52","author":"H Raza","year":"1996","unstructured":"Raza H, et al. Effect of bitter melon (Momordica charantia) fruit juice on the hepatic cytochrome P450-dependent monooxygenases and glutathione S-transferases in streptozotocin-induced diabetic rats. Biochem Pharmacol. 1996;52(10):1639\u201342.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"1016_CR18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejps.2005.05.004","volume":"26","author":"YC Kim","year":"2005","unstructured":"Kim YC, et al. Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. Eur J Pharm Sci. 2005;26(1):114\u201323.","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"1016_CR19","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.yjmcc.2008.03.019","volume":"44","author":"SL Hale","year":"2008","unstructured":"Hale SL, et al. Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol. 2008;44(6):954\u201367.","journal-title":"J Mol Cell Cardiol"},{"issue":"1\u20133","key":"1016_CR20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejphar.2012.03.010","volume":"683","author":"CY Deng","year":"2012","unstructured":"Deng CY, et al. Effect of ranolazine on rat intrarenal arteries in vitro. Eur J Pharmacol. 2012;683(1\u20133):211\u20136.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"1016_CR21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1476-5381.1996.tb15395.x","volume":"118","author":"TJ Allen","year":"1996","unstructured":"Allen TJ, Chapman RA. Effects of ranolazine on L-type calcium channel currents in guinea-pig single ventricular myocytes. Br J Pharmacol. 1996;118(2):249\u201354.","journal-title":"Br J Pharmacol"},{"issue":"8","key":"1016_CR22","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","volume":"43","author":"BR Chaitman","year":"2004","unstructured":"Chaitman BR, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375\u201382.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"1016_CR23","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/j.jacc.2009.12.055","volume":"55","author":"S Sossalla","year":"2010","unstructured":"Sossalla S, et al. Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol. 2010;55(21):2330\u201342.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"1016_CR24","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1161\/CIRCULATIONAHA.107.704890","volume":"116","author":"A Burashnikov","year":"2007","unstructured":"Burashnikov A, et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007;116(13):1449\u201357.","journal-title":"Circulation"},{"issue":"9646","key":"1016_CR25","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(08)61554-8","volume":"372","author":"DT Nash","year":"2008","unstructured":"Nash DT, Nash SD. Ranolazine for chronic stable angina. The Lancet. 2008;372(9646):1335\u201341.","journal-title":"The Lancet"},{"issue":"5","key":"1016_CR26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2165\/00003088-200645050-00003","volume":"45","author":"M Jerling","year":"2006","unstructured":"Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet. 2006;45(5):469\u201391.","journal-title":"Clin Pharmacokinet"},{"key":"1016_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/15569543.2019.1566263","author":"A Karimani","year":"2019","unstructured":"Karimani A, et al. Histopathological and biochemical alterations in non-diabetic and diabetic rats following acrylamide treatment. Toxin Reviews. 2019. https:\/\/doi.org\/10.1080\/15569543.2019.1566263.","journal-title":"Toxin Reviews"},{"issue":"1","key":"1016_CR28","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41598-020-57486-w","volume":"10","author":"P Seedevi","year":"2020","unstructured":"Seedevi P, et al. Anti-diabetic activity of crude polysaccharide and rhamnose-enriched polysaccharide from G. lithophila on streptozotocin (STZ)-induced in Wistar rats. Sci Rep. 2020;10(1):556.","journal-title":"Sci Rep"},{"key":"1016_CR29","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248\u201354.","journal-title":"Anal Biochem"},{"key":"1016_CR30","doi-asserted-by":"crossref","first-page":"110556","DOI":"10.1016\/j.ecoenv.2020.110556","volume":"196","author":"S Barangi","year":"2020","unstructured":"Barangi S, et al. Melatonin inhibits benzo(a)pyrene-induced apoptosis through activation of the Mir-34a\/Sirt1\/autophagy pathway in mouse liver. Ecotoxicol Environ Saf. 2020;196:110556.","journal-title":"Ecotoxicol Environ Saf"},{"issue":"1","key":"1016_CR31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.seizure.2013.09.012","volume":"23","author":"MI Read","year":"2014","unstructured":"Read MI, et al. Cardiac electrographic and morphological changes following status epilepticus: effect of clonidine. Seizure. 2014;23(1):55\u201361.","journal-title":"Seizure"},{"key":"1016_CR32","first-page":"1","volume":"50","author":"SL Bealer","year":"2011","unstructured":"Bealer SL, Metcalf CS, Little JG. Methods for ECG evaluation of indicators of cardiac risk, and susceptibility to aconitine-induced arrhythmias in rats following status epilepticus. J Vis Exp. 2011;50:1\u20135.","journal-title":"J Vis Exp"},{"key":"1016_CR33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijcard.2018.09.060","volume":"273","author":"E Nguyen","year":"2018","unstructured":"Nguyen E, et al. Ranolazine in patients with type 2 diabetes and chronic angina: a cost-effectiveness analysis and assessment of health-related quality-of-life. Int J Cardiol. 2018;273:34\u20138.","journal-title":"Int J Cardiol"},{"issue":"2","key":"1016_CR34","first-page":"251","volume":"55","author":"B Gawro\u0144ska-Szklarz","year":"2003","unstructured":"Gawro\u0144ska-Szklarz B, et al. Metabolism of lidocaine by liver microsomes from streptozotocin-diabetic rats. Pol J Pharmacol. 2003;55(2):251\u20134.","journal-title":"Pol J Pharmacol"},{"issue":"8","key":"1016_CR35","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1211\/jpp.58.8.0008","volume":"58","author":"B Gawronska-Szklarz","year":"2006","unstructured":"Gawronska-Szklarz B, et al. Lidocaine metabolism in isolated perfused liver from streptozotocin-induced diabetic rats. J Pharm Pharmacol. 2006;58(8):1073\u20137.","journal-title":"J Pharm Pharmacol"},{"issue":"4","key":"1016_CR36","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0006-2952(93)90547-A","volume":"46","author":"N Shimojo","year":"1993","unstructured":"Shimojo N, et al. Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes. Biochem Pharmacol. 1993;46(4):621\u20137.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"1016_CR37","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/dmd.110.035642","volume":"39","author":"N Hu","year":"2011","unstructured":"Hu N, et al. Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats. Drug Metab Dispos. 2011;39(3):419\u201325.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"1016_CR38","doi-asserted-by":"crossref","first-page":"420","DOI":"10.18433\/J3WC7G","volume":"10","author":"DY Lee","year":"2007","unstructured":"Lee DY, et al. Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1. J Pharm Pharm Sci. 2007;10(4):420\u201333.","journal-title":"J Pharm Pharm Sci"},{"issue":"2","key":"1016_CR39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/jbt.2570090203","volume":"9","author":"CR Barnett","year":"1994","unstructured":"Barnett CR, Flatt PR, Ioannides C. Modulation of the rat hepatic cytochrome P450 composition by long-term streptozotocin-induced insulin-dependent diabetes. J Biochem Toxicol. 1994;9(2):63\u20139.","journal-title":"J Biochem Toxicol"},{"issue":"3","key":"1016_CR40","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","volume":"291","author":"BR Chaitman","year":"2004","unstructured":"Chaitman BR, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309\u201316.","journal-title":"JAMA"},{"issue":"3","key":"1016_CR41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pharmthera.2011.11.003","volume":"133","author":"S Sossalla","year":"2012","unstructured":"Sossalla S, Maier LS. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol Ther. 2012;133(3):311\u201323.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1016_CR42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/187152571301150730113903","volume":"13","author":"K Polytarchou","year":"2015","unstructured":"Polytarchou K, Manolis AS. Ranolazine and its antiarrhythmic actions. Cardiovasc Hematol Agents Med Chem. 2015;13(1):31\u20139.","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"issue":"8","key":"1016_CR43","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.0000139333.83620.5D","volume":"110","author":"C Antzelevitch","year":"2004","unstructured":"Antzelevitch C, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110(8):904\u201310.","journal-title":"Circulation"},{"issue":"20","key":"1016_CR44","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","volume":"61","author":"M Kosiborod","year":"2013","unstructured":"Kosiborod M, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina). J Am Coll Cardiol. 2013;61(20):2038\u201345.","journal-title":"J Am Coll Cardiol"},{"key":"1016_CR45","doi-asserted-by":"crossref","unstructured":"Sandhiya S et al. Comparison of ranolazine and trimetazidine on glycemic status in diabetic patients with coronary artery disease - a randomized controlled trial. Journal of clinical and diagnostic research : JCDR, 2015. 9(1): p. OC01-OC5.","DOI":"10.7860\/JCDR\/2015\/10594.5448"},{"issue":"4","key":"1016_CR46","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s002100000378","volume":"363","author":"R L\u00e9tienne","year":"2001","unstructured":"L\u00e9tienne R, et al. Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the rat [correction of cat] cardiovascular system. Naunyn Schmiedebergs Arch Pharmacol. 2001;363(4):464\u201371.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"1016_CR47","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0003-9861(90)90479-I","volume":"279","author":"F Savabi","year":"1990","unstructured":"Savabi F, Kirsch A. Altered functional activity and anoxic tolerance in diabetic rat isolated atria. Arch Biochem Biophys. 1990;279(1):183\u20137.","journal-title":"Arch Biochem Biophys"},{"issue":"1\u20132","key":"1016_CR48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11010-006-9366-5","volume":"300","author":"FC Howarth","year":"2007","unstructured":"Howarth FC, et al. Effects of streptozotocin-induced diabetes on action potentials in the sinoatrial node compared with other regions of the rat heart. Mol Cell Biochem. 2007;300(1\u20132):39\u201346.","journal-title":"Mol Cell Biochem"},{"issue":"3","key":"1016_CR49","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1556\/APhysiol.101.2014.3.5","volume":"101","author":"H Khazraei","year":"2014","unstructured":"Khazraei H, Shafa M, Mirkhani H. Effect of ranolazine on cardiac microcirculation in normal and diabetic rats. Acta Physiol Hung. 2014;101(3):301\u20138.","journal-title":"Acta Physiol Hung"},{"issue":"5","key":"1016_CR50","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/1074248414524481","volume":"19","author":"I Mourouzis","year":"2014","unstructured":"Mourouzis I, et al. The beneficial effects of ranolazine on cardiac function after myocardial infarction are greater in diabetic than in nondiabetic rats. J Cardiovasc Pharmacol Ther. 2014;19(5):457\u201369.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"3","key":"1016_CR51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.toxlet.2007.03.010","volume":"170","author":"J Ueyama","year":"2007","unstructured":"Ueyama J, et al. Toxicity of diazinon and its metabolites increases in diabetic rats. Toxicol Lett. 2007;170(3):229\u201337.","journal-title":"Toxicol Lett"},{"issue":"1","key":"1016_CR52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1006\/phrs.1999.0568","volume":"41","author":"OA Al-Shabanah","year":"2000","unstructured":"Al-Shabanah OA, et al. Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats. Pharmacol Res. 2000;41(1):31\u20137.","journal-title":"Pharmacol Res"},{"issue":"6","key":"1016_CR53","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00000421-199812000-00015","volume":"21","author":"L Sadoff","year":"1998","unstructured":"Sadoff L. Overwhelming 5-fluorouracil toxicity in patients whose diabetes is poorly controlled. Am J Clin Oncol. 1998;21(6):605\u20137.","journal-title":"Am J Clin Oncol"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-021-01016-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-021-01016-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-021-01016-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T06:15:33Z","timestamp":1649139333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10840-021-01016-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1016"],"URL":"https:\/\/doi.org\/10.1007\/s10840-021-01016-9","relation":{},"ISSN":["1383-875X","1572-8595"],"issn-type":[{"value":"1383-875X","type":"print"},{"value":"1572-8595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,21]]},"assertion":[{"value":"22 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}